GLP-1 Therapies in Transition: Analytical and Clinical Insights for Experts

Explore GLP-1 receptor agonists with experts Judith Heij-Hadavi and Nicole Snow: molecular design, patient care, oral therapies, and analytical insights.

In the second episode of our GLP-1 Therapy Insights series, experts Judith Hey-Hadavi from Worldwide Clinical Trials and Nicole Snow from Olympia Pharmaceuticals discuss the evolution of GLP-1 receptor agonists from protein-based therapies to small-molecule options.

This episode examines the pharmacologic basis of GLP-1 adverse reactions, dose titration strategies, and patient-specific factors shaping therapy safety.

Judith Hey-Hadavi and Nicole Snow discuss GLP-1 receptor agonists, emphasizing personalized dosing, side effect management, and lifestyle support to optimize weight loss and patient outcomes.

Judith Hey-Hadavi and Nicole Snow discuss staying current on GLP-1 research and managing therapy side effects to support patient outcomes.

Judith Hey-Hadavi and Nicole Snow explore GLP-1 drug shortages, the safety and regulation of compounded alternatives, and strategies for patient education and proper administration to ensure effective and safe therapy.

The speakers highlight emerging trends in GLP-1 therapy, including personalized dosing, weight maintenance, combination treatments, and global innovations shaping the future of obesity management.